Literature DB >> 1829967

C4b-binding protein exacerbates the host response to Escherichia coli.

F Taylor1, A Chang, G Ferrell, T Mather, R Catlett, K Blick, C T Esmon.   

Abstract

Activated protein C is a plasma anticoagulant. For activated protein C to function as an anticoagulant, it must form a complex with protein S. Protein S anticoagulant activity is neutralized by formation of a reversible complex with C4b binding protein (C4bBP). C4bBP is an acute-phase plasma protein. When C4bBP levels increase, mass action forces the level of free protein S to decrease, giving rise to an acquired functional protein S deficiency. It has been proposed that these elevated C4bBP levels and the resultant acquired deficiency of protein S that occurs in inflammation could contribute to a hypercoagulable state. An experimental model to test this hypothesis was suggested by our previous studies that demonstrated that inhibition of protein C activation rendered baboons hypercoagulable in response to sublethal Escherichia coli infusion (J Clin Invest 79:918, 1987). We have extended these studies to examine the effect of inhibition of protein S activity with C4bBP in the host (baboon) response to infusion of sublethal concentrations of E coli organisms. Five sets of animals were studied: (1) those challenged with sublethal concentrations of E coli alone (0.4 x 10(10)/kg); (2) those supplemented only with C4bBP (20 mg/kg); (3) those challenged with the same level of E coli but supplemented with C4bBP (20 mg/kg); (4) those challenged with sublethal E coli and supplemented with C4bBP (20 mg/kg) and sufficient protein S (2.3 mg/kg) to fill the protein S binding sites on C4bBP; and (5) those challenged with lethal concentrations of E coli. Sublethal E coli infusion (group 1 animals) caused only an acute-phase response with no consumption of fibrinogen, detectable organ damage, or detectable tumor necrosis factor (TNF) in the plasma. C4bBP infusion (group 2 animals) resulted in no significant physiologic changes, no detectable plasma TNF, and little change in fibrinogen level. The group 3 animals, receiving both sublethal E coli and C4bBP, exhibited rapid consumption of fibrinogen, systemic organ damage, and detectable circulating TNF ultimately leading to death. The overall response of this group was very similar to the response of the group 5 animals receiving an LD100 dose of E coli. The group 4 animals, which were treated exactly as above except that C4bBP was supplemented with a slight excess of protein S, responded essentially like those that received sublethal E coli alone. These studies suggest that the elevation of C4bBP during an inflammatory response can contribute to fibrinogen consumption and vascular damage. This vascular damage may be associated with enhanced elaboration of cytokines like TNF.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829967

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Emerging therapies in severe sepsis.

Authors:  S J Finney; T W Evans
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 2.  Coagulation in sepsis.

Authors:  André Amaral; Steven M Opal; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2004-05-18       Impact factor: 17.440

Review 3.  New biological concepts on coagulation inhibitors.

Authors:  N Sala; J Fontcuberta; M L Rutllant
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

4.  Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis.

Authors:  B Isermann; S B Hendrickson; M Zogg; M Wing; M Cummiskey; Y Y Kisanuki; M Yanagisawa; H Weiler
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

5.  Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern.

Authors:  J P de Boer; A A Creasey; A Chang; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

Review 6.  Progress in the understanding of the protein C anticoagulant pathway.

Authors:  Björn Dahlbäck
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 7.  Coagulation disorders in septic shock.

Authors:  L G Thijs; J P de Boer; M C de Groot; C E Hack
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Complement activation in relation to capillary leakage in children with septic shock and purpura.

Authors:  J A Hazelzet; R de Groot; G van Mierlo; K F Joosten; E van der Voort; A Eerenberg; M H Suur; W C Hop; C E Hack
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

9.  Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits.

Authors:  B Arnljots; B Dahlbäck
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

10.  The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.

Authors:  R A Pixley; R De La Cadena; J D Page; N Kaufman; E G Wyshock; A Chang; F B Taylor; R W Colman
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.